

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM558741

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Athyrium Opportunities III Acquisition LP		01/23/2020	Limited Partnership: NEW YORK
RECEIVING PARTY DATA			
Name:	Veloxis Pharmaceuticals A/S		
Street Address:	Amerika Plads 37		
City:	København		
State/Country:	DENMARK		
Postal Code:	2100		
Entity Type:	Aktieselskab: DENMARK		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Registration Number:	2959361	MELTDOSE	
Registration Number:	4890115	ENVARUSUS XR	
CORRESPONDENCE DATA			
Fax Number:	2066237022		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	2066237580		
Email:	sepatents@klgates.com		
Correspondent Name:	K&L Gates LLP		
Address Line 1:	925 4th Ave.		
Address Line 2:	Ste 2900		
Address Line 4:	Seattle, WASHINGTON 98104-1158		
NAME OF SUBMITTER:	Brett O. White		
SIGNATURE:	/Brett O. White/		
DATE SIGNED:	01/23/2020		
Total Attachments: 6			
source=Veloxis - Release of IP Security Interests - Executed#page1.tif			
source=Veloxis - Release of IP Security Interests - Executed#page2.tif			
source=Veloxis - Release of IP Security Interests - Executed#page3.tif			

CH \$65.00 2959361

source=Veloxis - Release of IP Security Interests - Executed#page4.tif

source=Veloxis - Release of IP Security Interests - Executed#page5.tif

source=Veloxis - Release of IP Security Interests - Executed#page6.tif

**TERMINATION AND RELEASE OF SECURITY INTEREST
IN INTELLECTUAL PROPERTY**

This TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (this "Termination and Release"), dated as of January 23, 2020, is made by Athyrium Opportunities III Acquisition LP, as collateral agent (in such capacity, the "Collateral Agent"), in favor of Veloxis Pharmaceuticals A/S, a Danish Public limited liability company (the "Grantor"). All capitalized terms used but not otherwise defined herein have the meanings given to them in the Note Purchase Agreement (as defined below).

WITNESSETH

WHEREAS, pursuant to (a) that certain Note Purchase Agreement, executed and dated as of February 14, 2018, (the "Note Purchase Agreement"), by and among Veloxis Pharmaceuticals, Inc. (the "Issuer"), the Grantor, the other Guarantors from time to time party thereto, Athyrium Opportunities III Acquisition LP, as the initial purchaser, and the Collateral Agent, and (b) that certain Security Agreement, executed and dated as of February 14, 2018 (the "Security Agreement"), by and among the Issuer, the Grantor and the Collateral Agent, the Grantor pledged, assigned and granted to the Collateral Agent a security interest in the Collateral (as defined in the Security Agreement) including, without limitation, those items of Collateral listed on Schedule A hereto;

WHEREAS, the Grantor executed that certain (x) Notice of Grant of Security Interest in Patents (the "Patent Notice"), which was recorded with the United States Patent and Trademark Office on February 15, 2018, Reel No. 044942, Frame No. 0597 and Docket No. 035857.00017 and (y) Notice of Grant of Security Interest in Trademarks (the "Trademark Notice"), which was recorded with the United States Patent and Trademark Office on February 16, 2018, Reel No. 6274, Frame No. 0636 and Docket No. 035857.00017; and

WHEREAS, pursuant to that certain Payoff Letter, executed and dated as of the date hereof, all security interests of the Collateral Agent in the intellectual property Collateral (as defined in the Security Agreement) have been irrevocably terminated, released and discharged and the Collateral Agent has re-assigned and transferred all of its right, title and interest in the intellectual property Collateral (as defined in the Security Agreement) to the Grantor.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and without warranty or recourse of whatsoever kind, the Collateral Agent hereby irrevocably terminates, releases, discharges and cancels all of its security interests in the intellectual property Collateral, and re-assigns, re-conveys and re-transfers any right, title and interest that the Collateral Agent may have in the intellectual property Collateral to the Grantor and authorizes this Termination and Release to be recorded with the United States Patent and Trademark Office.

The terms of Section 17 of the Security Agreement are incorporated herein by reference, *mutatis mutandis*, and the parties hereto agree to such terms.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the Collateral Agent has caused this Termination and Release to be duly executed and delivered by its duly authorized officer as of the date first written above.

**ATHYRIUM OPPORTUNITIES III
ACQUISITION LP, as Collateral Agent**

**By: ATHYRIUM OPPORTUNITIES
ASSOCIATES III LP, its General Partner**

**By: ATHYRIUM OPPORTUNITIES
ASSOCIATES III GP LLC, the General
Partner of Athyrium Opportunities Associates III
LP**

By: _____
Name: Andrew C. Hyman
Title: Authorized Signatory

[Signature Page to Termination and Release of Security Interest in Intellectual Property]

**TRADEMARK
REEL: 006844 FRAME: 0004**

**SCHEDULE A
TO
RELEASE OF SECURITY INTEREST
IN PATENTS AND TRADEMARKS**

PATENTS

Title	Publication No.	Application No.	Filing Date	Country	Status	Patent No	Issue Date	Expiration Date	Assignee
MODIFIED RELEASE COMPOSITIONS COMPRISING TACROLIMUS		10/569,862	06/13/2006	USA - (US)	Granted - (G)	8,591,946	11/26/2013	07/03/2028	Veloxis Pharmaceuticals A/S
Solid dispersions comprising tacrolimus		10/569863	06/13/2006	USA - (US)	Granted - (G)	7994214	08/09/2011	08/30/2024	Veloxis Pharmaceuticals A/S
Tacrolimus For Improved Treatment Of Transplant Patients		12/499034	07/07/2009	USA - (US)	Granted - (G)	8685998	04/01/2014	01/20/2029	Veloxis Pharmaceuticals A/S
STABILIZED TACROLIMUS COMPOSITION		13/029304	02/17/2011	USA - (US)	Granted - (G)	9549918	01/24/2017	05/30/2028	Veloxis Pharmaceuticals A/S
MODIFIED RELEASE COMPOSITIONS COMPRISING TACROLIMUS		13/167095	06/23/2011	USA - (US)	Granted - (G)	8,617,599	12/31/2013	06/13/2026	Veloxis Pharmaceuticals A/S
MODIFIED RELEASE COMPOSITIONS COMPRISING TACROLIMUS		13/167160	06/23/2011	USA - (US)	Granted - (G)	8,623,410	01/07/2014	08/30/2024	Veloxis Pharmaceuticals A/S
MODIFIED RELEASE COMPOSITIONS COMPRISING TACROLIMUS		13/167,281	06/23/2011	USA - (US)	Granted - (G)	8,586,084	11/19/2013	08/30/2031	Veloxis Pharmaceuticals A/S

COMPRISING TACROLIMUS										
MODIFIED RELEASE COMPOSITIONS COMPRISING TACROLIMUS		13/167,334	06/23/2011	USA - (US)	Granted -(G)	8,623,411	01/07/2014	08/30/2024	Veloxis Pharmaceuticals A/S	
TACROLIMUS FOR IMPROVED TREATMENT OF TRANSPLANT PATIENTS		13/167420	06/23/2011	USA - (US)	Granted -(G)	8664239	03/04/2014	10/07/2029	Veloxis Pharmaceuticals A/S	
SOLID DISPERSIONS COMPRISING TACROLIMUS		13/178280	07/07/2011	USA - (US)	Granted -(G)	8486993	07/16/2013	08/30/2024	Veloxis Pharmaceuticals A/S	
MODIFIED RELEASE COMPOSITIONS COMPRISING TACROLIMUS		14/079414	11/13/2013	USA - (US)	Granted -(G)	8889185	11/18/2014	02/27/2026	Veloxis Pharmaceuticals A/S	
MODIFIED RELEASE COMPOSITIONS COMPRISING TACROLIMUS		14/079443	11/13/2013	USA - (US)	Granted -(G)	9161907	10/20/2015	11/13/2033	Veloxis Pharmaceuticals A/S	
MODIFIED RELEASE COMPOSITIONS COMPRISING TACROLIMUS		14/079466	11/13/2013	USA - (US)	Granted -(G)	8889186	11/18/2014	06/23/2031	Veloxis Pharmaceuticals A/S	
IMPROVED REGIMEN FOR SUPPRESSING ORGAN REJECTION		14/317500	06/27/2014	USA - (US)	Granted -(G)	9168246	10/27/2015	06/27/2034	Veloxis Pharmaceuticals A/S	
Porous Tablets As Carriers For Liquid Formulations	20150164812	14/635,950	03/02/2015	USA - (US)	Filed - (F)				Veloxis Pharmaceuticals A/S	

REGIMEN FOR SUPPRESSING ORGAN REJECTION		14/867,773	09/28/2015	USA - (US)	Granted - (G)	9,775,834	10/03/2017	06/27/2034	Veloxis Pharmaceuticals A/S
MODIFIED RELEASE COMPOSITIONS COMPRISING TACROLIMUS		14/855,624	09/16/2015	USA - (US)	Granted - (G)	9,757,362	09/12/2017	08/30/2024	Veloxis Pharmaceuticals A/S
SOLID DISPERSIONS COMPRISING TACROLIMUS		14/934,908	11/06/2015	USA - (US)	Granted - (G)	9,763,920	09/19/2017	08/30/2024	Veloxis Pharmaceuticals A/S
TACROLIMUS FOR IMPROVED TREATMENT OF TRANSPLANT PATIENTS	20160243091	15/041986	02/11/2016	USA - (US)	Filed - (F)				Veloxis Pharmaceuticals A/S
STABILIZED TACROLIMUS COMPOSITION	20170119675	15/405,879	01/13/2017	USA - (US)	Filed - (F)				Veloxis Pharmaceuticals A/S
MODIFIED RELEASE COMPOSITIONS COMPRISING TACROLIMUS		15/677,938	08/15/2017	USA - (US)	Filed - (F)				Veloxis Pharmaceuticals A/S
SOLID DISPERSIONS COMPRISING TACROLIMUS		15/676,727	08/14/2017	USA - (US)	Filed - (F)				Veloxis Pharmaceuticals A/S
REGIMEN FOR SUPPRESSING ORGAN REJECTION		15/682,275	08/21/2017	USA - (US)	Filed - (F)				Veloxis Pharmaceuticals A/S

TRADEMARK REGISTRATIONS

Trademark	Appl. #	Reg. #	Status	Country of Reg.	Appl. Dt	Reg. Dt	Classes	Owner
ENVARSUS XR	86/270,008	4,890,115	Registered	USA	5/2/2014	1/19/2016	05, 44	Veloxis Pharmaceuticals A/S
MELTDOSE	78/219,715	2,959,361	Registered	USA	2/27/2003	6/7/2005	42	Veloxis Pharmaceuticals A/S